Sign in Subscribe
Pharmaceutical industry

CuraGen's CG53135 Shows Promise in Preventing Oral Mucositis in Clinical Trial

Strategic Insights

— 2 min read

Results from a phase 1 clinical trial with CG53135 have shown that the drug is well-tolerated and supports the company's strategy to investigate its safety and efficacy in preventing oral mucositis (OM) in patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). The trial, presented at the ASH 46th Annual Meeting, involved 30 patients, of which 22 had data available, and showed that 81.8% did not develop severe grade 3 or 4 OM. The results suggest that CG53135 has the potential to prevent and treat OM, a severe side effect experienced by patients undergoing bone marrow transplants.

Key Takeaways:

  • The phase 1 clinical trial with CG53135 showed that the drug is well-tolerated and supports the company's strategy to investigate its safety and efficacy in preventing oral mucositis (OM).
  • The trial involved 30 patients, of which 22 had data available, and showed that 81.8% did not develop severe grade 3 or 4 OM.
  • The results suggest that CG53135 has the potential to prevent and treat OM, a severe side effect experienced by patients undergoing bone marrow transplants.
  • The primary objectives of the study were the evaluation of safety, tolerability, and pharmacokinetics following a single dose of CG53135.
  • The secondary objective of the study was to assess the development of OM using the WHO oral mucositis assessment scale.
  • Patients received a single dose of 0.03, 0.1, 0.2, or 0.33 mg/kg CG53135 administered intravenously 1 day after infusion of blood stem cells following high-dose chemotherapy.
  • Of the 22 patients presented, median age was 52.5 years, with diagnoses including multiple myeloma, non-Hodgkin lymphoma, acute myelogenous leukemia, and desmoplasmic round cell tumor.
  • High-dose chemotherapy conditioning regimens included high-dose melphalan, carboplatin and thiotepa, cyclophosphamide, carmustine, and etoposide, and busulfan and cyclophosphamide.
  • No drug-related serious adverse events were noted following treatment with CG53135.
  • Mild-moderate reactions including nausea, vomiting, tachycardia, hypotension, chills, and fever were observed.

Statistics:

  • 81.8% of patients did not develop severe grade 3 or 4 OM (n = 18/22).
  • The 0.03, 0.1, and 0.2 mg/kg single doses of CG53135 are being evaluated in a randomized, double-blind, placebo-controlled, multi-center phase 2 clinical trial for the prevention of OM in approximately 200 patients receiving HDCT.
  • A total of 30 patients were enrolled in the phase 1 clinical trial.

Sources:

  • CuraGen Corporation press release, "CuraGen Announces Results from Phase 1 Clinical Trial of CG53135 for the Prevention of Oral Mucositis in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation"
  • Health & Medicine Week, "CuraGen's CG53135 Shows Promise in Preventing Oral Mucositis in Clinical Trial"
  • ASH 46th Annual Meeting, "Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy (HDCT) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT)"

Read more